INIGEM 23989
INSTITUTO DE INMUNOLOGIA, GENETICA Y METABOLISMO
Unidad Ejecutora - UE
artículos
Título:
Immune response to racotumab in a child with relapsed neuroblastoma
Autor/es:
C. SAMPOR; M. D. GUTHMANN; A. SCURSONI ; W. CACCIAVILLANO; A. TORBIDONI; L. GALLUZZO; S. CAMARERO; J. LOPEZ; M. T. G. DE DÁVILA; L. FAINBOIM ; G. L. CHANTADA1
Revista:
Frontiers in Oncology
Editorial:
Frontiers in Oncology
Referencias:
Lugar: Georgetown University; Año: 2012 vol. 10 p. 10 - 20
ISSN:
2234-943X
Resumen:
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
